authors.affiliation: 1 Klinik für Rheumatologie, Stadtspital Triemli, Zürich.
authors.forename: Dagmar
authors.initials: D
authors.lastname: Wildpaner
authors.affiliation: 1 Klinik für Rheumatologie, Stadtspital Triemli, Zürich.
authors.forename: Chiara
authors.initials: C
authors.lastname: Pavese
authors.affiliation: 1 Klinik für Rheumatologie, Stadtspital Triemli, Zürich.
authors.forename: Marcel
authors.initials: M
authors.lastname: Weber
mesh_terms: D015502:Absorptiometry, Photon; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D000069448:Denosumab / Q000009:adverse effects / Q000627:therapeutic use; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use; D042241:Early Diagnosis; D061345:Early Medical Intervention; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000175:diagnosis / Q000517:prevention & control*; D012307:Risk Factors
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000069448:Denosumab
keywords: Bisphosphonate; Denosumab; Langzeitbehandlung; Osteoporose; Osteoporosis; Ostéoporose; bisphosphonates; denosumab; long-term therapy; traitement à long terme